Qualigen Therapeutics Inc (QLGN)
BIOTECHNOLOGY
Last updated: Nov 13, 2026 at 4:00 PM ET
Qualigen Therapeutics Inc (QLGN) Financials: Revenue, Profit and Cash Flow
Qualigen Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2024, down 100.0% from the year before. That year, net income was -$6.16M, operating cash flow was -$6.33M and free cash flow was -$6.33M. The quarter ended Sep 30, 2025 had revenue of $0 and net income of -$2.04M.
Revenue and Margins
The company reported no revenue in the fiscal year ended Dec 2024, with an operating loss of $5.76M.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2024 | $0 | -100.0% | N/A | N/A | N/A |
| Dec 2023 | $5.20M | +4.4% | -0.1% | -217.2% | -257.8% |
| Dec 2022 | $4.98M | -11.9% | 13.7% | -360.0% | -422.1% |
| Dec 2021 | $5.65M | +31.3% | 23.4% | -400.9% | -316.6% |
| Dec 2020 | $4.31M | -22.5% | -66.9% | -262.5% | -474.2% |
| Dec 2019 | $5.56M | -4.2% | 28.4% | -27.0% | -32.2% |
| Dec 2018 | $5.80M | -40.6% | -292.9% | -582.2% | -290.7% |
| Dec 2017 | $9.78M | N/A | -80.8% | -159.1% | -80.4% |
| Dec 2016 | N/A | N/A | N/A | N/A | N/A |
| Dec 2015 | N/A | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Dec 2024, the net loss narrowed from the year before. In the quarter ended Sep 2025, the net loss widened from the same quarter a year earlier.
Annual
| Line item | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $5.20M | $4.98M | $5.65M | $4.31M | $5.56M | $5.80M | $9.78M | N/A | N/A |
| Cost of revenue | N/A | $5.21M | $4.30M | $4.33M | $7.19M | $3.98M | $17.00M | $7.90M | $18.45M | $8.91M |
| Gross profit | N/A | -$4.50K | $680.80K | $1.32M | -$2.88M | $1.58M | -$17.00M | -$7.90M | -$18.45M | -$8.91M |
| Research and development | $1.20M | $5.21M | $6.84M | $11.72M | $3.55M | $1.21M | $11.37M | $2.87M | $13.29M | $2.26M |
| Operating income | -$5.76M | -$11.30M | -$17.94M | -$22.66M | -$11.30M | -$1.50M | -$33.79M | -$15.55M | -$36.62M | -$17.57M |
| Net income | -$6.16M | -$13.42M | -$21.03M | -$17.90M | -$20.42M | -$1.79M | -$16.87M | -$7.86M | -$18.38M | -$9.18M |
| EBITDA | -$5.24M | -$11.30M | -$13.84M | -$22.66M | -$11.16M | N/A | -$33.78M | -$15.55M | -$36.62M | -$17.57M |
Quarterly
| Line item | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $2.24M | $0 | $0 | $0 | $0 | $0 | $7.94M | $1.63M | $1.61M | $1.39M |
| Gross profit | N/A | N/A | $1.12M | N/A | -$123.43K | -$754.29K | -$364.38K | -$4.50K | $2.35M | $610.49K | $342.34K | $293.73K |
| Operating income | -$1.43M | -$1.68M | -$1.33M | -$973.04K | -$1.27M | -$1.74M | -$1.41M | -$2.27M | -$2.78M | -$3.55M | -$3.69M | -$4.41M |
| Net income | -$2.04M | -$1.69M | -$855.82K | -$855.82K | -$1.79M | -$1.58M | -$2.03M | -$2.47M | -$3.66M | -$3.46M | -$4.11M | -$6.37M |
Balance Sheet
As of Dec 2024, cash and equivalents of $1.17M were 24.9% of total assets of $4.69M, against total liabilities of $2.01M.
Annual
| Line item | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $4.69M | $2.03M | $19.08M | $22.84M | $29.13M | $2.80M | $15.32M | $22.83M | $7.24M | $16.04M |
| Current assets | $4.68M | $1.17M | $10.82M | $20.80M | $28.22M | $2.21M | $15.28M | $22.80M | $7.20M | $16.01M |
| Cash and equivalents | $1.17M | $401.80K | $7.03M | $17.54M | $23.98M | $1.70M | $7.81M | $22.63M | $7.05M | $15.82M |
| Total liabilities | $2.01M | $4.14M | $10.32M | $6.27M | $10.83M | $1.70M | $5.93M | $2.71M | $3.13M | $1.35M |
| Short-term debt | N/A | N/A | N/A | N/A | N/A | $100.47K | N/A | N/A | N/A | N/A |
| Long-term debt | N/A | N/A | N/A | N/A | N/A | $305.81K | N/A | N/A | N/A | N/A |
| Shareholder equity | $2.68M | -$2.10M | $7.24M | $16.56M | $18.29M | $1.10M | $9.39M | $20.13M | $4.10M | $14.68M |
Quarterly
| Line item | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $43.47M | $3.96M | $4.69M | $4.69M | $2.31M | $534.41K | $1.00M | $2.03M | $4.32M | $13.15M | $15.91M | $19.08M |
| Total liabilities | $4.92M | $5.61M | $2.01M | $2.01M | $4.45M | $4.81M | $4.52M | $4.14M | $5.96M | $9.84M | $9.71M | $10.32M |
| Cash and equivalents | $38.78M | $331.60K | $1.17M | $1.17M | $388.15K | $118.69K | $543.22K | $401.80K | $2.07M | $1.34M | $4.36M | $7.03M |
| Shareholder equity | $38.55M | -$1.65M | $2.68M | $2.68M | -$2.14M | -$4.28M | -$3.52M | -$2.10M | -$1.64M | $2.03M | $4.87M | $7.24M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2024.
Annual
| Line item | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$6.33M | -$10.30M | -$13.25M | -$14.73M | -$9.76M | $57.33K | -$13.33M | -$7.40M | -$15.21M | -$5.72M |
| Capital expenditures | $0 | $10.30M | $319.12K | $141.36K | $210.19K | $194.48K | $2.01K | $7.68K | $8.06K | $17.00K |
| Free cash flow | -$6.33M | -$20.61M | -$13.57M | -$14.87M | -$9.97M | -$137.15K | -$13.33M | -$7.41M | -$15.22M | -$5.74M |
| Dividends paid | $87.60K | N/A | $2.90M | N/A | N/A | N/A | $2.54M | $3.11M | N/A | $327.57K |
| Investing cash flow | -$1.91M | $4.22M | -$183.76K | -$141.36K | -$160.56K | -$194.48K | -$225.83K | -$7.68K | -$8.06K | -$17.00K |
| Financing cash flow | $9.01M | -$550.00K | $2.91M | $8.43M | $33.76M | $165.14K | $5.48M | $22.99M | $6.44M | $18.81M |
Quarterly
| Line item | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$2.14M | -$1.10M | -$2.27M | -$2.27M | -$1.80M | -$1.47M | -$783.59K | -$5.67M | $929.74K | -$2.93M | -$2.63M | -$2.24M |
| Capital expenditures | $0 | $0 | $0 | $0 | $2 | $2 | $0 | $0 | $246.42K | $48.41K | $198.01K | $244.37K |
| Free cash flow | -$2.14M | -$1.10M | -$2.27M | -$2.27M | -$1.80M | -$1.47M | -$783.59K | -$5.67M | $683.32K | -$2.98M | -$2.83M | -$2.48M |
Frequently Asked Questions About QLGN
What is Qualigen Therapeutics' annual revenue?
Qualigen Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2024.
How fast is Qualigen Therapeutics' revenue growing?
Revenue was down 100.0% for the fiscal year ended Dec 31, 2024 compared with the year before.
Is Qualigen Therapeutics profitable?
No. Qualigen Therapeutics reported net income of -$6.16M for the fiscal year ended Dec 31, 2024.
How much free cash flow does QLGN generate?
For the fiscal year ended Dec 31, 2024, operating cash flow of -$6.33M minus capital expenditures of $0 produced free cash flow of -$6.33M.
How much debt does Qualigen Therapeutics have?
The balance sheet dated Dec 31, 2024 reported cash and equivalents of $1.17M.
QLGN pages: Overview, Financials